A Secondary Analysis of DANFLU-1 Trial - High vs Standard Dose Influenza Vaccine in CKD | ESC 2024

Khurram Nasir, MBBS, FACC, JACC Associate Editor and Tor Biering-Sorenson, MD, MPH, PhD, discuss the importance of influenza vaccines for patients with chronic kidney disease (CKD), particularly in the context of the DANFLU-1 study. The guest, who is the lead and senior author of a secondary analysis of this study, explains how the research compares the effectiveness of high-dose versus standard-dose influenza vaccines in CKD patients. The findings suggest that while high-dose vaccines may offer better protection against influenza-related complications, the results are hypothesis-generating and further research, such as the ongoing DANFLU-2 trial, is needed to provide definitive answers. The conversation highlights the broader significance of flu vaccines in preventing not just infections but also cardiovascular and renal complications in high-risk populations like CKD patients.
key takeaways from the video are:
1. Importance of Influenza Vaccination in CKD Patients: The video emphasizes the significant role of influenza vaccines in protecting patients with chronic kidney disease (CKD) from not only the flu but also from downstream cardiovascular and renal complications.
2. DANFLU 1 Study Insights: The DANFLU 1 study compared high-dose and standard-dose influenza vaccines in CKD patients. The analysis suggests that the high-dose vaccine may offer better protection, although the results are considered hypothesis-generating and not yet conclusive.
3. Ongoing Research with DANFLU 2: The ongoing DANFLU 2 trial, involving over 300,000 participants, is expected to provide more definitive answers on the effectiveness of high-dose influenza vaccines in CKD patients, with results anticipated in the near future.
4. Broader Implications for Vaccine Uptake: The discussion underscores the need for increased vaccine uptake in high-risk populations like CKD patients and highlights the broader benefits of flu vaccines beyond preventing infection, including reducing cardiovascular and renal risks.

Related content:
#jacc #jaccjournals #esccongress